“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at chemotherapy for advanced cancer of the stomach or gastro oesophageal junction that has continued to grow (PEP0206)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at the chemotherapy drugs irinotecan, docetaxel and PEP02 for advanced cancer of the stomach, or cancer where the food pipe (oesophagus) meets the stomach (cancer of the gastro oesophageal junction).
Treatment for cancer of the stomach and treatment for gastro oesophageal junction cancer usually includes chemotherapy, surgery or radiotherapy, or a combination of these. If your cancer comes back after the first type of chemotherapy, you may have more chemotherapy to help relieve symptoms and slow down cancer growth. Doctors call this further chemotherapy second line treatment.
There is a choice of possible chemotherapy drugs that doctors can use as second line treatment. In this trial, they looked at 3 drugs – irinotecan, docetaxel and PEP02. When the trial was done, irinotecan and docetaxel were already used to treat this type of cancer. PEP02 was a newer form of irinotecan being tested in this trial.
The aims of the trial were find out
Summary of results
This trial showed PEP02 was as good as docetaxel and a little better than irinotecan for advanced cancer of the stomach or gastro oesophageal junction.
This trial recruited 132 people from several countries around the world. Everyone who took part had advanced cancer which had continued to grow despite having other treatment.
The people taking part were put into one of 3 treatment groups at random, so there were 44 people in each group. They all had treatment once every 3 weeks, for as long as it was helping.
- Group 1 had PEP02
- Group 2 had irinotecan
- Group 3 had docetaxel
The research team looked at how many people’s cancer got smaller. They were able to assess this in 124 people who took part. They found that the cancer got smaller in
- 6 out of 41 people who had PEP02
- 3 out of 43 people who had irinotecan
- 7 out of 40 people who had docetaxel
They also looked at how long it was before the cancer started to grow and how long the people taking part lived for. These were similar in all 3 groups.
When they looked at the side effects, they found that more people who had irinotecan or PEP02 had side effects compared to those who had docetaxel. The most common side effect of PEP02 and irinotecan was diarrhoea. The most common side effect of docetaxel was hair loss.
The research team concluded that in this trial, PEP02 and docetaxel worked about as well as each other, but a little better than irinotecan.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor David Cunningham
NIHR Royal Marsden Biomedical Research Centre
Peter Stebbings Memorial Charity